AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups

AstraZeneca lung disease drug shows 30% reduction in COPD exacerbations

AstraZeneca announced its experimental drug tozorakimab achieved approximately 30% reductions in moderate and severe COPD exacerbations compared to standard therapy in two late-stage studies presented at the European Respiratory Society Congress.